THY1 and metastatic neoplasm: CD90+CXCR4+ present a better surface marker of CTSCs than CD133+CD90+, promoting the formation of tumor spheres in vitro, tumor development in primary and subsequent secondary and tertiary transplantation experiments, and distal metastatic tumors following subcutaneous transplantation [62].